Author Correction: Reevaluation of antibody-dependent enhancement of infection in anti-SARS-CoV-2 therapeutic antibodies and mRNA-vaccine antisera using FcR- and ACE2-positive cells (Scientific Reports, (2022), 12, 1, (15612), 10.1038/s41598-022-19993-w)

Abstract

The original version of this Article contained an error, where the mention of “mRNA” was inappropriate. As a result, in the Introduction, “Therapeutic Ab drugs targeting SARS-CoV-2 S-protein have shown high preventive efficacy against disease development1,2,3. In addition, current SARS-CoV-2 mRNA vaccines for humans also target the S-protein on viruses as a critical antigen4. These mRNA vaccines generate robust neutralizing Abs5,6,7,but for both Ab drugs and vaccines targeting the S-protein, the possible induction of Ab-dependent enhancement (ADE) of infection is a concern8,9,10,11.” now reads: “Therapeutic Ab drugs targeting SARS-CoV-2 S-protein have shown high preventive efficacy against disease development1,2,3. In addition, current SARS-CoV-2 vaccines for humans also target the S-protein on viruses as a critical antigen4. These vaccines generate robust neutralizing Abs5,6,7, but for both Ab drugs and vaccines targeting the S-protein, the possible induction of Ab-dependent enhancement (ADE) of infection is a concern8,9,10,11.” The original Article has been corrected.